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Purpose. Despite initial enthusiasm for endovascular aortic repair, few descriptions of longer-term follow-up of any
endovascular device have been published. This paper represents the experience of a single centre with the Vanguard device
over a 5-year period.
Methods. Fifty-five patients with a median age of 71 years (range 45–87 years) and aneurysm diameter of 59 mm (45–
84 mm) received a bifurcated Vanguard stent-graft between December 1995 and July 1999. Follow-up was according to the
Eurostar criteria (clinical assessment, plain film radiography and computed tomography) at 1, 3, 6, 12, 18 and 24 months
and then annually thereafter.
Results. All primary stent deployments were successful. Median duration of surgery was 120 min (70–360 min). Median
post-operative stay was 3 days (1–19 days) with a peri-operative mortality of 5.5%. In the follow-up period (median 40
months, range 6–64 months) there was one aneurysm associated death, and 14 deaths due to other causes. There have been
three device migrations, 12 occluded graft limbs, four type II endoleaks and nine type III endoleaks. At 48 months, this has
resulted in a survival rate of 67%, an endoleak free survival of 81% and intervention free survival of 59% (Kaplan–Meier).
Conclusion. Medium term results with the Vanguard device appear to be at least equivalent to open repair with regard to
morbidity and mortality. Nevertheless, several delayed complications appear to be related to endograft limb distortion.
Important lessons have been learnt in relation to the deployment of bifurcated endografts to reduce the incidence of secondary
limb related problems.
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Introduction
Since the inception of ‘Endovascular Aortic Aneurysm
Repair’ (EVAR) in the last decade of the 20th century,
the feasibility of the procedure has been demonstrated
with many different home made and commercial
devices. The earliest reports described the application
of tube grafts fixed to the endoluminal aspect of the
aorta with either Palmaz or Gianturco Z stents.1,2
These first studies showed that endoluminal methods
were sufficient to exclude an aneurysm in the short
term, but further follow-up data demonstrated an
unacceptable incidence of distal endoleak. This was
related to the relatively short distal aortic necks
present in the majority of patients and also to the
natural history, whereby there is continued expansion
of the distal aortic neck despite aneurysm exclusion.3,4
The next generation of endograft designs were
centred on the tapered aorto-iliac graft with femoro-
femoral crossover5 or the bifurcate configuration. The
‘aorto-mono-iliac’ endografts expanded the range of
anatomical settings in which EVAR could be applied
and could easily be made up in theatre, whereas the
bifurcate systems were emerging through trials by the
pioneers6,7 in a ‘semi-commercial’ setting. The first
commercially available bifurcated endografts were the
EVT device (Endo Vascular Technologies, Menlo Park,
CA) and the Stentor (Mintec Ltd, Bahamas; precursor
of the Vanguard).
Several groups reported early success in abdominal
aortic aneurysm (AAA) exclusion using the Stentor/
Vanguard I systems.6 The device had been subjected to
two main design changes after Boston Scientific took
over manufacture in 1996: application of a seamless
Meadox surgical grade polyethylene graft material
(Fig. 1) and improvements in the number and grade of
sutures between the graft material and the supporting
stent framework. However, the early enthusiasm for
the Vanguard system was subsequently tempered by
reports of suture breakage, endograft distortion and
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junctional disconnections.8,9 These complications
appeared to indicate potential weaknesses in the
basic structure of the early Vanguard system and
perhaps heralded further problems in the medium
term.8
The Vanguard device fell out of favour in the United
Kingdom in 1998, when rival stent graft systems
appeared to offer more robust designs with a wider
size range and thus greater applicability to the AAA
population. In addition, the Medical Devices Agency
(of the UK National Health Service) issued a ‘safety
notice’ later in 1999, warning users of the possibility of
suture breakages10 and to follow strict guidelines in
terms of the regular surveillance of each implanted
Vanguard system.
Despite the initial world-wide enthusiasm for
EVAR, and perhaps because of the reported mechan-
ical problems with several of the first and second
generation devices, few descriptions of the longer term
follow up of any endovascular device have been
published. This paper represents the experience of a
single centre with the Vanguard device over a period
of 5 years and which effectively includes the ‘learning
curve’ for EVAR.
Materials and Methods
Recruitment of AAA patients for endovascular repair
took place between December 1995 and July 1999. The
EVAR programme was approved by the Local Ethical
Committee and every patient informed of the inves-
tigational nature of the technique. All devices were
implanted by an ‘endovascular team’ which contained
both vascular surgeons and interventional radiol-
ogists. The first 25 EVAR procedures were performed
in the Angiographic suite in Radiology. The sub-
sequent cases have been undertaken in a dedicated
Endovascular Operating Theatre on a fixed angio-
graphic table with a ceiling-mounted C-arm. All cases
were done under general anaesthetic.
Study patients
Fifty-five patients received a bifurcated Vanguard
stent-graft during the study period. These 55 patients
consisted of 49 men (89.1%) and six women (10.9%)
with a median age of 71 years (range 45–87 years).
Forty-eight patients presented with an asymptomatic
aneurysm, six patients were symptomatic and one
patient presented with a contained rupture. Pre-
operative anaesthetic risk was measured by the
American Society of Anaesthesiologists’ (ASA) score.
Twenty nine (52.7%) patients were graded as ASA II,
23 (41.8%) were graded ASA III and three (5.5%) were
ASA IV.
Median aneurysm diameter was 59 mm (range 45–
84 mm) with a median neck diameter of 22 mm (range
14.7–24.5 mm). Median proximal neck length was
21 mm (range 14–100 mm).
Device
The Vanguard bifurcated endovascular aortic graft
(Boston Scientific Ltd, St Albans, Herts.) is a modular
device derived from the Mintec Stentor system in 1996.
It is composed of a primary component, the aorto-iliac
endoprosthesis, with an attachment site for a second-
ary component or contralateral iliac limb (Fig. 1). Both
these components are made of a nitinol wire frame-
work covered by a polyester fabric. On exposure to
blood at body temperature, the nitinol wire self-
expands to a pre-set diameter. In this way the stent-
graft becomes closely applied to the endoluminal
surfaces of the aorta in the proximal neck and the iliac
vessels at the distal attachment sites. Three pairs of
externally projecting barbs help to further anchor the
device in the proximal neck. The contralateral limb
expands within the junctional area of the aorto-iliac
prosthesis and is thus stabilised by a combination of
radial force and friction. The primary and secondary
components are each completely sealed within poly-
ethylene introduction catheters, 22 French Gauge (FG)
and 12 FG, respectively. Each introduction system
required preparation by flushing with ice-cold saline.
Procedure
All patients received a general anaesthetic in this early
series. The procedure was covered by a single intra-
venous injection of gentamicin (160 mg) and metroni-
dazole (400 mg). The main device was usually inserted
via the common femoral artery through a small
transverse inguinal incision. A bolus of 5000 IU
heparin was given prior to device insertion. The
Fig. 1. The Vanguard bifurcated endovascular aortic graft
(Boston Scientific Ltd). The device comprises of a primary
component (the aorto-iliac endoprosthesis) with an attach-
ment site for a secondary component or contralateral iliac
limb. The device is made up of a nitinol framework covered
by a polyester fabric.
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secondary component was generally inserted into the
contralateral femoral artery using a standard percuta-
neous Seldinger technique.
Angiography was performed in two planes after
device insertion in order to assess the integrity of the
proximal and distal fixation sites, as well as the
junctional area of the completed bifurcated graft. If
there was evidence of a significant leak of contrast into
the aneurysm sac then a further intervention was
usually indicated, either additional balloon expansion
of the graft, insertion of a proximal cuff or a distal
extension.
Follow up
All patients were entered into both the National
(RETA) and the European (EUROSTAR) EVAR Regis-
tries and underwent regular evaluation by clinical
assessment, plain film radiography and computed
tomography (CT). These tests were performed in the
first week following EVAR and then at 1, 3, 6, 12, 18
and 24 months. Subsequent assessments were at 12-
month intervals. Morbidity and mortality were
recorded. All endoleaks, graft limb occlusions or
other device related complications were investigated.
When re-intervention was indicated, endovascular
methods of treatment were considered prior to open
surgery.
Statistical analysis
Median values and ranges were calculated, with
statistical significance determined by the Wilcoxon
signed rank test. Cumulative survival tables were
calculated by the Kaplan–Meier method.
Results
All primary stent graft deployments in this study were
successful and there were no open conversions. The
median duration of surgery was 120 min (range 70–
360 min) with an estimated median blood loss of
200 ml (range 30–1000 ml). One patient had a total
blood loss of 2500 ml, due to an additional procedure
that was unrelated to the Vanguard insertion.
Difficulty in deploying the stent was found in 18
(32.7%) patients. Twenty-four additional procedures
were performed intraoperatively (Table 1) to improve
access, to treat an endoleak or to resolve a graft limb
occlusion. All these procedures contributed to success-
ful stent deployment.
Post-operative course
Twelve (21.8%) patients required admission to the
intensive care unit post-operatively. Median stay for
these patients was 12 h (range 4–48 h). The median
total post-operative stay (including ICU and ward
stay) was 3 days (range 1–19 days).
There were a total of 10 (19%) post-operative
systemic complications (renal impairment 5, myocar-
dial infarction 2, stroke 1, transient ischaemic attack 1,
transfusion reaction 1) and three false aneurysms, each
at a site of femoral artery puncture for the deployment
of an introducer (Table 2). All were treated surgically.
The peri-operative mortality was 5.5% (Table 3).
Early device related complications
Pre-discharge CT scans revealed six endoleaks (11.5%).
These consisted of one type I endoleak (1.9%) and five
type II endoleaks (9.6%). The patient with the type I
endoleak underwent laparotomy with external band-
ing of the proximal neck. This patient subsequently
died in the post-operative period. Of the five type II
endoleaks, four had sealed spontaneously by the time
of the first CT scan at 1 month. The type II endoleak in
the fifth patient persisted and was embolised at 6 and
12 months.
Survival
The median follow-up period for the 51 patients who
survived beyond 30 days was 40 months (range 6–64
months), with a mean of 38.6 ^ 14.9 months. There
were 15 further deaths (29.4%) in this follow-up period
and the causes of death are listed in Table 4. One
patient was lost to follow-up after 18 months. CT scans
up to this point had shown no evidence of a leak or any
increase in aneurysm size (Fig. 2).
Two of the late deaths were related to the AAA and
subsequent endovascular repair. The first was a 74-
year-old female (ASA II) who underwent an unevent-
ful primary procedure. She was admitted as an
emergency to an outlying hospital, 16 months after
the initial operation. The cause of death was a
ruptured AAA. The protocol CT scan at 12 months
had shown no sign of an endoleak although, in
retrospect, the plain film demonstrated possible distal
migration of the proximal margin of the stent graft. It
is probable that an endoleak had developed shortly
prior to aneurysm rupture.
The second patient, a 71-year-old female (ASA II)
with no pre-existing renal disease developed renal
impairment following partial obstruction of the left
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renal artery ostium with the proximal margin of the
graft material. Initially, the renal function appeared to
improve and serial CT scans to 18 months showed no
endoleak. However, the left kidney did reduce in size
over a period of months. The patient eventually died
22 months after stent insertion, having developed end-
stage renal failure.
Delayed device related complications
During the follow-up period after the first month,
there have been 26 device related complications in 20
patients.
Device migration
There have been three device migrations. The first,
which was not associated with an endoleak, was
successfully treated with an aortic cuff at 33 months
(Fig. 3). The second, which was associated with a
proximal type III endoleak, required graft revision
with an aorto-uni-iliac device at 59 months. The third
graft migration was associated with buckling of the
graft limbs and this patient is currently awaiting
further investigations and treatment.
Graft limb occlusions
There were 12 occluded graft limbs (12%) in 11 (21.6%)
patients with a median onset of 18 months (range 24 h
to 36 months) (Fig. 4). One patient was treated
conservatively. The remaining 10 patients (with 11
episodes of graft occlusion) were successfully treated
by embolectomy (1), thrombectomy (1), thrombolysis
(1) and femoro-femoral crossover graft (8).
There has been one disconnection of an occluded
graft limb at 3 years. This was asymptomatic and no
treatment has been necessary. One patient developed
buckling of the graft at the contra-limb junction at 3
years and this has simply been observed. One patient
developed intermittent claudication due to pre-exist-
ing atheromatous disease at 12 months and improved
following the insertion of bilateral iliac Wallstents.
Endoleaks
In the follow-up period, 13 endoleaks have been
identified in eight patients (15.7%).
Of the 13 endoleaks that developed, median onset
24 months (range 3–59 months), during the follow-up
period, there have been four type II endoleaks and
nine type III endoleaks.
Half of the type II endoleaks sealed spontaneously
within 2 months of being identified and no further
Table 1. Additional intra-operative procedures required
Procedure Number
Additional introducer required 5
Additional limb extension 3
Proximal cuff 2
Wallstent 9
Fem-fem crossover 1
Endarterectomy 1
Thrombolysis 1
Placement of second stent co-axially 2
Table 2. Post-operative complications
Systemic Access site
Renal impairment (5) False aneurysm (3)—All required intervention
Renal artery embolization (1)
Cholesterol microembolization (1)
Graft occluded single renal artery (1)
Cause not determined (2)
Myocardial infarction (2)
Stroke (1)
Transient ischaemic attack (1)
Transfusion reaction (1)
Fig. 2. Kaplan–Meier survival curves of patient survival,
freedom from intervention and freedom from secondary
endoleak.
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treatment was necessary. The remaining two type II
endoleaks have only recently occurred and are under
observation. Of the nine type III endoleaks (Fig. 5(A)
and (B)), one patient developed a proximal type III
endoleak following graft migration and a tear in the
device between the upper body ring and the main
body at 59 months. This was treated by re-stenting. Six
type III endoleaks have required limb extensions and
two have required a further aorto-uni-iliac device. All
have remained sealed at follow-up.
Aneurysm evolution
Within the follow-up period, there has been only a
small decrease in the median aneurysm diameter (Fig.
6) and this has not been shown to be statistically
significant (Table 5).
Discussion
This single centre experience with the Vanguard
endovascular device is based on the comprehensive
follow up of all patients treated since the device
became available in 1995. No patient required conver-
sion to open repair during the primary procedures in
this series. The rate of primary endoleak was only 11%,
which is well within the rate quoted in the literature of
10–47%.11,12 Most of these early leaks were dealt with
by endovascular means and none resulted in surgical
conversion.
There was no evidence to suggest that peri-
operative morbidity or mortality was significantly
increased during this early experience. A peri-operat-
ive mortality of 5.5% is similar to that associated with
open repair. It has been suggested that the less
traumatic endovascular procedure may be a more
appropriate method of treatment for patients at higher
surgical risk. Our experience is that patients who are
graded ASA IV appear to do relatively poorly in the
post-operative period and this has led us to consider
the use of regional or local anaesthesia for selected
cases. The Zurich endovascular group have reported
significantly lower peri-operative mortality using local
anaesthesia for EVAR procedures.13
However, the main reason for our study was to
assess the longer-term outcome after EVAR and
during the follow-up period at least one of our stented
patients died with a ruptured AAA. The CT scans
prior to this event had not shown any evidence of an
endoleak or increasing aneurysm diameter. It has been
postulated that this patient may have developed a
proximal endoleak that rapidly increased the size of
the aneurysm and caused the subsequent rupture. The
possibility of such an event draws attention to the fact
that EVAR is still an investigational procedure. Never-
theless, whilst surveillance is important, present
protocols and the sudden nature of some problems
suggests that even extreme diligence to follow up will
not prevent all complications. At present, however,
regular surveillance is a mandatory requirement for
patients entering the UK EVAR trials or the national
registry.14
The high incidence of delayed or secondary device
related complications in this series (35%) is related to
the frequent occurrence of ‘kinking’ or angulation of
the stent graft within the aneurysm sac. The Liverpool
group has extensively investigated this problem15,16
and suggests the cause is related to shortening of the
excluded aneurysm sac as it reduces in volume with
time. The endoleaks that result from limb kinking are
type III endoleaks17 in relation to either disconnection
of the contralateral limb from the main device or due
Table 3. Peri-operative mortality (30 days)
Age Sex ASA Cause of death Time of event
79 F III Myocardial infraction (following laparotomy for proximal endoleak) Day 6 post-op
81 M IV Myocardial infraction Day 3 post-op
61 M III Spontaneous cerebral haemorrhage (following thrombolysis for
occluded graft limb)
24 h post-op
74 M II Sepsis (unknown aetiology) 30 days post-op
Peri-operative mortality: 5.5%. 30-day mortality: 7.3%.
Table 4. Cause of death in follow-up period
Cause of death Months survived
Debility/MRSA 6
Carcinoma bronchus 12
Unknown cause 14
Congestive cardiac failure 14
Oesophageal carcinoma 15
AAA rupture 16
UTI/Septicaemia 17
Myocardial infarction 20/20
Gastric carcinoma 21
Chronic renal failure 21/22
Non-Hodgkins lymphoma 24
Bladder carcinoma 35
Pneumonia 43
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to upward migration of either limb from the distal
implantation site in the common iliac artery. These
endoleaks can usually be easily treated by percuta-
neous endovascular means.
The incidence of endoleaks and occlusions related
to delayed limb kinking and (or) migration highlights
the importance of allowing a significant ‘overlap’ in
Fig. 3. Plain abdominal antero-posterior radiograph showing
proximal graft migration with significant kinking at the
junctional area.
Fig. 4. Angiographic appearance of occluded left limb. This
was successfully treated by a femoro-femoral crossover
graft.
Fig. 5. (A) CT appearance of a large type III endoleak arising
from the area just proximal to the junctional region. (B) Type
III endoleak: a large distal endoleak just above the junctional
area secondary to a hole in the stent fabric.
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the junctional areas of all modular devices and the
necessity of ensuring the longest possible distal
‘attachment’ to the common iliac artery. The further
development of all stent grafts should include par-
ticular attention to the radial strength of the ‘endo-
limbs’. This factor is particularly important in those
device designs that rely on ‘raising the aortic bifur-
cation’ to a significant degree and thus result in
relatively long endolimbs. It is likely that the use of
devices with longer main bodies and with junctional
areas only just superior to the native aortic bifurcation
will result in fewer long-term problems related to limb
distortion or dislocation.
Effective exclusion of the aneurysm sac should lead
to diameter reduction of the aneurysm,18,19 but this
change is not immediately visible in the data from our
series. If the data collected during the follow up of
stented aneurysms that had endoleaks is separated
from those of the AAAs that continue to show primary
freedom from endoleak, a different picture may
emerge. The available literature on the post-endograft
changes in diameter of the aneurysm neck suggests
that the disease process in the aorta continues despite
the exclusion of the aneurysm.20 This is consistent with
our experience although further careful tracking of
neck sizes is required to assess whether the increase in
neck diameters is due to the underlying pathological
process. This aspect of the disease process holds great
implications for the future fixation of endovascular
devices and is the subject of ongoing studies.
Conclusions
Endovascular repair of AAAs has been shown to be
feasible and the medium term results appear accep-
table and are at least equivalent to open repair with
regard to morbidity and mortality. The delayed
complications appear to be related mainly to distortion
of the endograft limbs. Further design modifications of
the Vanguard system were implemented to strengthen
the endolimbs. Important lessons have been learnt in
relation to the deployment of bifurcated endografts so
as to reduce the incidence of secondary limb related
problems. The longer-term outcomes remain to be
observed.
References
1 Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal
graft implantation for abdominal aortic aneurysms. Ann Vasc
Surg 1991;5(6):491–499.
2 Mirich D, Wright KC, Wallace S, Yoshioka T, Lawrence Jr
DD, Charnsangavej C, Gianturco C. Percutaneously placed
endovascular grafts for aortic aneurysms: feasibility study.
Radiology 1989;170(3 Pt 2):1033–1037.
3 EVT Investigators, Endovascular Technologies Inc., Matsumara
JS, Chaikof EL. Continued expansion of aortic necks after
Endovascular repair of abdominal aortic aneurysms. J Vasc Surg
1998;28(3):422–430.
4 Wever JJ, de Nie AJ, Blankensteijn JD, Broeders I, Mali W,
Eikelboom B. Dilatation of the proximal neck of infrarenal aortic
aneurysms after endovascular repair. Eur J Vasc Endovasc Surg
2000;19:197–201.
5 Yusuf SW, Baker DM, Hind RE, Chuter TA, Whitaker SC,
Wenham PW, Gregson RH, Hopkinson BR. Endoluminal
transfemoral abdominal aortic aneurysm repair with aorto-uni-
iliac graft and femorofemoral bypass. Br J Surg 1995;82(7):916.
6 Mialhe C, Amicabile C, Becquemin JP. Endovascular treatment
of infrarenal abdominal aortic aneurysms by the stentor system:
preliminary results of 79 cases. J Vasc Surg 1997;26:199–209.
7 Quinonones-Baldrich WJ, Deaton DH, Mitchell RS et al.
Preliminary experience with the endovascular technologies
bifurcated endovascular aortic prosthesis in a calf model. J Vasc
Surg 1995;22:370–381.
8 Guidoin R, Marois Y, Douville Y, King MW, Castonguay M,
Traore A, Formichi M, Staxrud LE, Norgren L, Bergeron P,
Bequemin JP, Egana JM, Harris PL. First generation aortic
endografts: analysis of explanted Stentor devices from the
EUROSTAR Registry. J Endovasc Ther 2000;7(2):105–122.
9 Riepe G, Heintz C, Chafke N, Morlock M, Gross-Fengels W,
Imig H. Stent wire fractures and mesh loosening in explanted
endovascular prosthesis. Zentralbl Chir 2000;125(1):22–26.
10 Medical Device Agency Safety Notice. SN 1999 (03) Vanguard
endovascular aortic graft: late complications: February; 1999.
11 Becquemin J-P, Lapie V, Favre J-P, Rousseau H. Mid-term results
of a second generation bifurcated endovascular graft for
Fig. 6. Evolution of maximum aneurysm diameter.
Table 5. Change in aneurysm diameter
CT scans available Median (range) Significance
Pre-operative 51 59 nm (45–84)
12 months 45 58 mm (42–80) NS
18 months 32 56 mm (41–80) NS
24 months 29 56.5 mm (42–80) NS
36 months 16 56 mm (34–81) NS
48 months 9 53 mm (33–81) NS
Wilcoxon-signed rank.
Mid-term Results of Vanguard 317
Eur J Vasc Endovasc Surg Vol 27, March 2004
abdominal aortic aneurysm repair: the French Vanguard Trial.
J Vasc Surg 1999;30(2).
12 Schurink G, Aarts N, van Bockel J. Endoleak after stent-graft
treatment of abdominal aortic aneurysm: a meta-analysis of
clinical studies. Br J Surg 1999;86(5):581–587.
13 Lachat M, Pfammatter T, Schneider D, Schmidli J, Hilfiker
P, Koppensteiner R, Vogt PR, Turina M. Endovascular
treatment of the abdominal aortic aneurysm: assessment,
implantation technique, after-care and results. Schweiz Med
Wochenschr 1999;129(4):113–119.
14 Brennan J, Harris PL, Gilling-Smith GL, Bakran A. Vascular
Surgical Society of Great Britain and Ireland: endovascular
aneurysm repair: the need for randomized controlled trials. Br J
Surg 1999;86(5):711.
15 Gould D, Edwards R, McWilliams R, Rowlands P, Martin J,
White D, Fear S, Bakran A, Brennan J, Gilling-Smith G,
Harris PL. Graft distortion after endovascular repair of
abdominal aortic aneurysm: association with sac morphology
and mid-term complications. Cardiovasc Intervent Radiol 2000;23:
358–363.
16 Harris P, Brennan J, Martin J, Gould D, Bakran A, Gilling-
Smith G, Buth J, Gevers E, White D. Longitudinal aneurysm
shrinkage following endovascular aortic repair: a source of
intermediate and late complications. J Endovasc Surg 1999;6(1):
11–16.
17 Harris PL. The highs and lows of endovascular aneurysm
repair: the first two years of the Eurostar Registry. Ann R Coll Surg
Engl 1999;81(3):161–165.
18 Matsumura JS, Pearce WH. Pre-existing thrombus and aortic
aneurysm size change after endovascular repair. J Surg Res 1999;
81(1):11–14.
19 Rhee RY, Eskandari MK, Zajko AB, Makaroun MS. Long-term
fate of the aneurysmal sac after endoluminal exclusion of
abdominal aortic aneurysms. J Vasc Surg 2000;32(4):689–696.
20 Resch T, Ivancev K, Brunkwall J, Nirhov N, Malina M,
Lindbald B. Midterm changes in aortic aneurysm morphology
after endovascular repair. J Endovasc Ther 2000;7(4):279–285.
Accepted 4 December 2003
S. J. Holtham et al.318
Eur J Vasc Endovasc Surg Vol 27, March 2004
